Kinetic versus allosteric mechanisms to explain insurmountable antagonism and delayed ligand dissociation

Neurochemistry International

Volumn 51, Issue 5, 2007, Pages 254-260

  Vauquelin, Georges ^a   Szczuka, Anna ^b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Antagonist; Dissociation; Kinetics; Negative cooperativity; Non competitivity; Radioligand; Rebinding; Receptor

Indexed keywords

CANDESARTAN; CELL RECEPTOR; INSULIN; LOSARTAN; RADIOLIGAND; RECEPTOR BLOCKING AGENT; TRITIUM;

ALLOSTERISM; ARTICLE; BINDING SITE; CELL SURFACE; COMPLEX FORMATION; DISSOCIATION; ISOTOPE LABELING; KINETICS; LIGAND BINDING; MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; RADIOASSAY;

ANIMALS; DRUG ANTAGONISM; HUMANS; KINETICS; LIGANDS; RADIOLIGAND ASSAY; RECEPTORS, CELL SURFACE; RECEPTORS, DRUG;

EID: 34548515751     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2007.05.005     Document Type: Article

References (50)

1. Abbott A.J., and Nelsestuen G.L. The collisional limit: an important consideration for membrane-associated enzymes and receptors. FASEB J. 2 (1988) 2858-2866
2. Ariens E.J., Van Rossum J.M., and Simmonis A.M. A theoretical basis of molecular pharmacology. Arzneimittel Forschung 6 (1956) 611-621
3. Berg H.C., and Purcell E.M. Physics of chemoreception. Biophys. J. 20 (1977) 193-219
4. Bodenstein J., Venter D.P., and Brink C.B. Phenoxybenzamine and benextramine, but not 4-Diphenylacetoxy-N-[2-chloroethyl]piperidine hydrochloride, display irreversible noncompetitive antagonism at G protein-coupled receptors. J. Pharm. Exp. Ther. 314 (2005) 891-905
5. Christopoulos A. From 'captive' agonism to insurmountable antagonism: demonstrating the power of analytical pharmacology. Clin. Exp. Pharmacol. Physiol. 28 (2001) 223-229
6. Christopoulos A., and Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54 (2003) 323-374
7. DeLisi C. The effect of cell size and receptor density on ligand-receptor reaction rate constants. Mol. Immunol. 18 (1981) 507-511
8. DeLisi C., and Wiegel F.W. Effect of nonspecific forces and finite receptor number on rate constants of ligand-cell bound-receptor interactions. Proc. Natl. A. Sci. U.S.A. 78 (1981) 5569-5572
9. De Meyts P., Bianco A.R., and Roth J. Site-site interactions among insulin receptors. Characterization of negative cooperativity. J. Biol. Chem. 251 (1976) 1877-1888
10. De Vries C.P., van Haeften T.W., and van der Veen E.A. Demonstration of insulin induced enhancement of insulin dissociation from its receptor in H35 rat hepatoma cells in spite of a linear scatchard plot. Endocrine Res. 17 (1991) 331-342
11. Dunlop J., Pass I., and Ennis C. The cholecystokinin-B receptor antagonist L-740,093 produces an insurmountable antagonism of CCK-4 stimulated functional response in cells expressing the human CCK-B receptor. Neuropeptides 32 (1998) 157-160
12. 1 receptor antagonists: the role of tight antagonist binding. Eur. J. Pharmacol. 372 (1999) 199-206
13. 1 receptor-transfected Chinese hamster ovary cells. Eur. J. Pharmacol. 367 (1999) 413-422
14. Furchgott R.F. The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. Adv. Drug Res. 3 (1966) 21-55
15. Gaddum J.H., Hameed K.A., Hathaway D.E., and Stephens F.F. Quantitative studies of antagonists for 5-hydroxytryptamine. Q. J. Exp. Physiol. Cogn. Med. Sci. 40 (1955) 49-74
16. Gill R., Verma C., Wallach B., Urso B., Pitts J., Wollmer A., De Meyts P., and Wood S. Modelling of the disulphide-swapped isomer of human insulin-like growth factor-1: implications for receptor binding. Prot. Eng. 12 (1999) 297-303
17. Goldstein B., Posner R.G., Torney D.C., Erickson J., Holowka D., and Baird B. Competition between solution and cell surface receptors for ligand. Dissociation of hapten bound to surface antibody in the presence of solution antibody. Biophys. J. 56 (1989) 955-966
18. 2-adrenergic receptor that exploits the domain structure of G protein-coupled receptors. J. Med. Chem. 40 (1997) 3871-3886
19. Helmerhorst E. The insulin-receptor interaction: is the kinetic approach for inferring negative-cooperative site-site interactions valid?. Biochem. Biophys. Res. Commun. 147 (1987) 399-407
20. Hunyady L., Vauquelin G., and Vanderheyden P. Agonist induction versus conformational selection during activation of a G protein-coupled receptor. Trends Pharmacol. Sci. 24 (2003) 81-86
21. Kenakin T. The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol. Rev. 48 (1996) 413-463
22. Kukkonen J.P., Huifang G., Jansson C.C., Wurster S., Cockcroft V., Savola J.M., and Akerman K.E.O. Different apparent modes of inhibition of alpha2A-adrenoceptor by alpha2 adrenoceptor antagonists. Eur. J. Pharmacol. 335 (1997) 99-105
23. 1 receptor activation. J. Biol. Chem. 277 (2002) 23107-23110
24. 2-like receptors. Can they be classified with the available antagonists?. Br. J. Pharmacol. 88 (1986) 585-593
25. Limbird L.E. In: Limbird L.E. (Ed). Cell Surface Receptors: A Short Course in Theory and Methods (1996), Kluwer Academic Publishers, Boston 61-122
26. Liu Y.J., Shankley N.P., Welsh N.J., and Black J.W. Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible, synoptic action. Br. J. Pharmacol. 106 (1992) 233-241
27. Ljung B. Vascular selectivity of felodipine. Drugs 29 (1985) 46-58
28. 1 angiotensin receptor is generated by angiotensin II induction. Biochemistry 35 (1996) 16435-16442
29. 1 antagonism. J. Pharmacol. Exp. Ther. 273 (1995) 753-761
30. Park L.S., Friend D.J., Schmierer A.E., Dower S.K., and Namen A.E. Murine interleukin 7 (IL-7) receptor. Characterization on an IL-7-dependent cell line. J. Exp. Med. 171 (1990) 1073-1089
31. Paton W.D.M., and Rang H.P. A kinetic approach to the mechanism of drug action. Adv. Drug Res. 3 (1966) 57-80
32. Pihlavisto M., and Scheinin M. Functional assessment of recombinant human α(2)-adrenoceptor subtypes with cytosensor microphysiometry. Eur. J. Pharmacol. 385 (1999) 247-253
33. Pin J.P., Kniazeff J., Liu J., Binet V., Goudet C., Rondart P., and Prezeau L. Allosteric functioning of dimeric class C G protein-coupled receptors. FEBS J. 272 (2005) 2947-2955
34. Pin J.P., Neubig R., Bouvier M., Devi L., Filizola M., Javitch J.A., Lohse M.J., Milligan G., Palczewski K., Parmentier M., and Spedding M. International union of basic and clinical pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol. Rev. 59 (2007) 5-13
35. Rios C.D., Jordan B.A., Gomes I., and Devi L.A. G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacol. Ther. 92 (2001) 71-87
36. l receptor antagonist. Br. J. Pharmacol. 107 (1992) 1173-1180
37. Shoup D., and Szabo A. Role of diffusion in ligand binding to macromolecules and cell-bound receptors. Biophys. J. 40 (1982) 33-39
38. Sutter A., Riopelle R.G., Harris-Warrick R.M., and Shooter E.M. Nerve growth factor receptors. Characterization of two distinct classes of binding sites on chick embryo sensory ganglia cells. J. Biol. Chem. 254 (1979) 5972-5982
39. 2 receptor. Pharmacology 59 (1999) 1-10
40. Urizar E., Montanelli L., Loy T., Bonomi M., Swillens S., Gales C., Bouvier M., Smits G., Vassart G., and Costagliola S. Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. EMBO J. 24 (2005) 1954-1964
41. 1 receptors. Br. J. Pharmacol. 126 (1999) 1057-1065
42. 1 receptors expressed in CHO-K1 cells. Biochem. Pharmacol. 59 (2000) 927-935
43. Vauquelin G., Fierens F.L.P., and Vanderheyden P.M.L. Mechanisms of angiotensin II antagonism. In: Epstein M., and Brunner H.R. (Eds). Competitive vs. Non-Competitive Inhibition in Angiotensin II Receptor Antagonists (2000), Harley & Belfus Inc., Philadelphia 105-118
44. 1 receptor antagonists. J. Renin Angiotensin Aldosterone Syst. 2 (2001) S24-S31
45. 1 receptors and their non-peptide antagonists. Biochem. Pharmacol. 61 (2001) 277-284
46. 1 receptor antagonism: the need for different antagonist binding states of the receptor. Trends. Pharmacol. Sci. 22 (2001) 343-344
47. Vauquelin G., Van Liefde I., and Vanderheyden P. Models and methods for studying insurmountable antagonism. Trends. Pharmacol. Sci. 23 (2002) 514-518
48. Vauquelin G., Van Liefde I., Birzbier B.B., and Vanderheyden P.M.L. New insights in insurmountable antagonism. Fundam. Clin. Pharmacol. 16 (2002) 263-272
49. Vauquelin G., and Van Liefde I. G protein-coupled receptors: a count of 1001 conformations. Fundam. Clin. Pharmacol. 19 (2005) 45-56
50. 1 receptor binding and protection by Candesartan: comparison to other biphenyl-tetrazole sartans. J. Hypertens. 24 (2006) S23-S30